Aron Knickerbocker

Aron Knickerbocker has a diverse and extensive work experience in the biotechnology and pharmaceutical industry. Aron is currently the Chief Executive Officer of Aulos Bioscience and a Board Member of Phenomic AI. In 2020, they served as the Chairman of the Board for KAHR-Medical Ltd. Prior to that, they co-founded RayzeBio in 2019 and held the positions of Chairman and Founding CEO. Aron also worked as a Corporate Strategy and Business Development Consultant from 2020 to 2021. From 2009 to 2019, Knickerbocker held various roles at Five Prime Therapeutics, Inc., including President and Chief Executive Officer, Director of the Board of Directors, Chief Operating Officer, Chief Business Officer, and Vice President of Business Development. Before that, they worked at Genentech as a Senior Director of Business Development, Johnson & Johnson as a Director of Commercial Development, and Amgen as a Senior Manager of Corporate Development. Aron started their career at Bristol Myers Squibb as a Research Scientist. Overall, Knickerbocker has demonstrated a strong leadership and strategic expertise throughout their career in the industry.

Aron Knickerbocker pursued higher education starting in 1987 at Washington University in St. Louis, where they earned a Bachelor's degree with Honors in Biology in 1991. Continuing their educational journey, they enrolled at the University of Michigan - Stephen M. Ross School of Business from 1994 to 1996. Aron achieved an MBA with Distinction, specializing in Business Administration and Management.